We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF

92 hedge funds and large institutions have $276M invested in iShares US Pharmaceuticals ETF in 2016 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 27 increasing their positions, 27 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

100% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 10

76% more capital invested

Capital invested by funds: $157M → $276M (+$119M)

42.05% more ownership

Funds ownership: 78.78%120.84% (+42%)

10% more funds holding

Funds holding: 8492 (+8)

0% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 27

63% less call options, than puts

Call options by funds: $537K | Put options by funds: $1.47M

Holders
92
Holders Change
+8
Holders Change %
+9.52%
% of All Funds
2.3%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
20
Increased
27
Reduced
27
Closed
10
Calls
$537K
Puts
$1.47M
Net Calls
-$934K
Net Calls Change
-$1.54M
Name Holding Trade Value Shares
Change
Change in
Stake
S
101
SignatureFD
Georgia
-$7K -150 Closed
Mariner
102
Mariner
Kansas
-$7K -138 Closed

IHE Hedge Fund Activity: Q4 2016 in Review

92 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q4 2016, worth a combined $276M — up 76% from $157M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new IHE positions and 10 closed out — a net gain of 10 holders — while 27 added to existing stakes and 27 trimmed.

The largest buyer was Clal Insurance, opening a new position worth an estimated $64.8M. The largest seller was Jane Street, exiting entirely with an estimated $4.48M sold.

  • 92 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q4 2016, up from 84 in Q3 2016.
  • Funds reported $276M of iShares US Pharmaceuticals ETF stock for Q4 2016, up 76% quarter-over-quarter.
  • 20 funds opened new iShares US Pharmaceuticals ETF positions in Q4 2016 and 10 closed out, a net change of +10 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q4 2016 was Clal Insurance, an estimated $64.8M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q4 2016 was Jane Street, an estimated $4.48M sold.

Based on aggregated 13F filings for Q4 2016.